[Efficacy of mono- and polychemotherapy in patients with advanced ovarian cancer]

The effectiveness of mono- and polychemotherapy as components of combined treatment of 142 cases of stage IV ovarian cancer was evaluated. Remission was 1.3 times more frequent (85.7%) and its mean duration (10.8 months) was longer in patients who had received polychemotherapy than in cases of monochemotherapy, the respective figures in the latter group being 66.7% and 5.7 months. A 3-year survival and life-span were identical in both study groups. Poly- and monochemotherapy are equally effective in treatment of primary ovarian cancer.